omniture
logo
Search
江苏康宁杰瑞生物制药有限公司
Media Room

Latest News

rss

Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research

SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announcedClini...

2022-02-24 09:41 3448

Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052

SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, tha...

2022-02-11 09:31 4639

Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046

* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswir...

2022-01-13 10:46 3956

IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharma...

2022-01-05 11:49 5247

Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046

SUZHOU, China, Dec. 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced dosi...

2021-12-23 09:13 3805

Posters Highlighting clinical data of KN026 presented at SABCS 2021

SUZHOU, China, Dec. 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharma...

2021-12-09 12:20 2952

IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE

SUZHOU, China, Nov. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...

2021-11-24 09:35 3058

Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC

SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a p...

2021-10-29 09:36 3100

IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE

SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharm...

2021-10-21 10:31 3497

Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046

* ENREACH-LUNG-01 is a multi-center, randomized, double-blind, placebo-controlled phase III clini...

2021-10-18 10:19 3178

Alphamab Oncology Reports 2021 Interim Results and Business Highlights

SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the...

2021-08-30 10:51 4829

Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China

SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced toda...

2021-08-24 15:08 3501
12345